Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab

scientific article published on August 2013

Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/CKJ/SFT065
P8608Fatcat IDrelease_h5iupo6okzcvlhcw4l4fplm4gi
P932PMC publication ID3888095
P698PubMed publication ID24422172
P5875ResearchGate publication ID259722696

P50authorRodney D. GilbertQ41580948
Timothy H J GoodshipQ115122955
P2093author name stringLouise K Stanley
Steven A Hardy
Darren J Fowler
Elizabeth M Angus
P2860cites workAtypical hemolytic uremic syndromeQ21202864
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeQ24634697
The development of atypical hemolytic uremic syndrome depends on complement C5Q28300378
Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumourQ28370405
Complement-dependent clearance of apoptotic cells by human macrophagesQ30442812
Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynxQ33338736
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disordersQ33371578
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adultsQ33405246
Thrombotic Microangiopathy and Renal Failure Associated with Antineoplastic ChemotherapyQ33476240
Cisplatin-associated hemolytic uremic syndromeQ33491119
Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.Q33499022
Role of complement and perspectives for intervention in ischemia-reperfusion damage.Q37831329
Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findingsQ46157733
Carboplatin-associated thrombotic microangiopathic hemolytic anemia.Q55485142
Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumourQ83135449
P433issue4
P304page(s)421-425
P577publication date2013-08-01
P1433published inClinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association)Q26842221
P1476titleCisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab
P478volume6

Reverse relations

cites work (P2860)
Q26750692Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
Q33783126Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
Q27003211Current treatment of atypical hemolytic uremic syndrome
Q33411956Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement
Q92134406Eculizumab in chemotherapy-induced thrombotic microangiopathy
Q42858176Factors influencing treatment of atypical hemolytic uremic syndrome.
Q37032691The Genetics of Ultra-Rare Renal Disease
Q33432099The alternative pathway of complement and the thrombotic microangiopathies
Q42368351Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab.
Q36241014Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients

Search more.